

PROGRAMMA CONFERENZE FORMATIVE IOSI 2021

DATA	RELATORE	TITOLO
20.01.2021	Prof Roger Von Moos Head of Medical Oncology and Hematology, Kantonsspital Graubünden, Chur (CH) Contatto: Roger.vonMoos@ksgr.ch	The importance of clinical trials in oncology and barriers to clinical trial participation
24.02.2021	Prof. Emanuele Zucca Vice Head of Oncology Institute of Southern Switzerland (IOSI) and Co-founder of International Extranodal Lymphoma Study Group (IELSG), Bellinzona (CH) Contatto: emanuele.zucca@eoc.ch	Clinical research in rare entities: practice changing achievements of the IELSG
17.03.2021	Prof. Andrea Alimonti Head Molecular Oncology of Institute of Oncology Research (IOR), Bellinzona (CH) Contatto: andrea.alimonti@ior.usi.ch	The surprising role of the gut microbiota in prostate cancer progression and therapy
21.04.2021	Prof. Miklos Pless Head of Oncology, Dep of Medical Oncology, Kantonsspital Winterthur (CH) Contatto: miklos.Pless@ksw.ch	Updates on the treatment of NSCLC
19.05.2021	Prof. Robert Coleman Emeritus Professor of Medical Oncology, University of Sheffield (UK) Contatto: r.e.coleman@sheffield.ac.uk	Bone health and cancer therapy
16.06.2021	Prof. Olivier Michielin Associate professor of Department of Oncology UNIL CHUV, Lausanne (CH) Contatto: olivier.michielin@unil.ch	Molecular screening of cancer patients: when and how
15.09.2021	Prof. Ruth Plummer Professor at Translational and Clinical Research Institute, Newcastle University Centre for Cancer, Faculty of Medical Sciences, Newcastle University (UK) Contatto: Ruth.Plummer@newcastle.ac.uk	DNA repair defects and their targeting in cancer
13.10.2021	Prof. George Coukos Head of Department of Oncology UNIL CHUV and of Immuno-oncology service, Lausanne (CH) Contatto: George.Coukos@chuv.ch	Update on CAR-T cells and future directions
17.11.2021	tbd	New immunotherapy combinations. How to balance toxicity and increased efficacy?